These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7542050)

  • 21. [Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs].
    Sénéchal A; Landry P; Deschamps R; Lessard M
    Encephale; 2002; 28(6 Pt 1):567-9. PubMed ID: 12506270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects for pharmacotherapy of schizophrenia.
    Pickar D
    Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
    [No Abstract]   [Full Text] [Related]  

  • 24. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
    Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat.
    Dugovic C; Wauquier A; Janssen PA
    Neuropharmacology; 1989 Dec; 28(12):1431-3. PubMed ID: 2482460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
    Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
    Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risperidone: clinical safety and efficacy in schizophrenia.
    Borison RL; Pathiraja AP; Diamond BI; Meibach RC
    Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA; Awouters FH
    Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone.
    Cohen LJ
    Pharmacotherapy; 1994; 14(3):253-65. PubMed ID: 7524043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
    Kitaichi K; Yamada K; Hasegawa T; Furukawa H; Nabeshima T
    Jpn J Pharmacol; 1994 Oct; 66(2):181-9. PubMed ID: 7532732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
    Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone for the treatment of schizophrenia: does it have a niche?
    Price PL
    S D J Med; 1995 May; 48(5):160-1. PubMed ID: 7541553
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.
    Addington DE; Jones B; Bloom D; Chouinard G; Remington G; Albright P
    Clin Ther; 1993; 15(5):917-26. PubMed ID: 7505716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Vainer JL; Bélanger MC; Turnier L; Beaudry P; Roy JY; Miller R
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1129-41. PubMed ID: 7531355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey on the pharmacodynamics of the new antipsychotic risperidone.
    Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
    Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist.
    Panocka I; Pompei P; Massi M
    Brain Res Bull; 1993; 31(5):595-9. PubMed ID: 7684315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical review of risperidone.
    Chouinard G; Arnott W
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S89-95. PubMed ID: 7504574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
    Yoshimura R; Nakamura J; Ueda N; Terao T
    Int Clin Psychopharmacol; 2000 May; 15(3):175-80. PubMed ID: 10870876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol.
    Megens AA; Awouters FH; Niemegeers CJ
    Psychopharmacology (Berl); 1988; 95(4):493-6. PubMed ID: 2463650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A; Janssen PF; Megens AA; Leysen JE
    Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.